Bausch Health Companies Inc. (BHC) Analysts See $1.14 EPS

October 13, 2018 - By Vivian Park

Analysts expect Bausch Health Companies Inc. (TSE:BHC) to report $1.14 EPS on November, 6.They anticipate $0.16 EPS change or 12.31 % from last quarter’s $1.3 EPS. T_BHC’s profit would be $394.95M giving it 7.04 P/E if the $1.14 EPS is correct. After having $1.20 EPS previously, Bausch Health Companies Inc.’s analysts see -5.00 % EPS growth. The stock increased 2.39% or $0.75 during the last trading session, reaching $32.1. About 1.51M shares traded or 85.92% up from the average. Bausch Health Companies Inc. (TSE:BHC) has 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Bausch Health Companies Inc. develops, makes, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company has market cap of $11.12 billion. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. It currently has negative earnings. The firm also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News